Portugal

State will participate 15% of obesity medicines in patients monitored

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 14:56:25 UTC.

Briefings

The Portuguese State announced it will fund 15% of obesity medications for patients in specific multidisciplinary care plans, provided they are prescribed by endocrinologists, internal medicine doctors, or pediatricians. This measure, published in October 2026, requires patients to be integrated into the EMO unit and follow the PCIPO pathway. While the State aims to improve access, private hospital associations criticized the policy as discriminatory, noting it may create long waiting lists and waste system capacity.

Key points

• The State will fund 15% of obesity medications for patients in specific multidisciplinary care plans.
• Access requires prescription by endocrinologists, internal medicine doctors, or pediatricians in the EMO unit.

Context

This initiative is part of the PNPGO program coordinated by the DGS to prevent and manage obesity. The measure aims to improve access to essential medications for patients with obesity.

Limitations

The measure applies only to patients in specific care plans and requires specialist prescriptions. Private hospital associations criticized the policy as discriminatory, noting it may create long waiting lists and waste system capacity. The diploma only enters into effect 120 days after publication.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 01:47:59 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiadt26ft3uk4pir7dtc3apmqbwoumahj6x33mj2a5ho6oespv4uvy